Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorphenamine maleate is a first-generation alkylamine antihistamine that acts as a potent H1 receptor antagonist. It works by competitively blocking histamine H1 receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby alleviating symptoms of allergic reactions. This injectable formulation, developed by Shanghai Hefeng Pharmaceutical, is primarily indicated for the rapid relief of severe allergic conditions such as urticaria, angioedema, and allergic reactions to blood or plasma. As a first-generation antihistamine, it is known to cross the blood-brain barrier, which can lead to sedative effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorphenamine maleate.